A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis. J of Skin 2020, 4 (5), s35. https://doi.org/10.25251/skin.4.supp.35.